A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Summary

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

Timeline

Start

2023-02-13

Primary completion

2025-08-13

Completion

2025-08-13

Outcome

Outcome not reported

Stopped (Business): “The study was terminated due to a strategic decision to discontinue development.”

Drugs

Indications